Effect of stellate ganglion block on intracranial vascular and prognosis in patients with Moyamoya disease

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2100050185

Enrollment

Unknown

Registered

2021-08-21

Start date

2021-08-23

Completion date

Unknown

Last updated

2022-04-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Moyamoya disease

Interventions

SGB group:Ipsilateral stellate ganglion block was performed with 0.2% ropivacaine 8ml

control group:Routine extracranial artery bypass grafting only

Eligibility

Sex/Gender

All

Age

12 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Patients with accurate diagnosis of moyamoya disease who are to undergo unilateral extracranial artery bypass grafting; 2. Preoperative sober cooperation, can cooperate to complete all the examination and operation; 3. No known allergic history to the experimental drug; 4. Sign the informed consent.

Exclusion criteria

Exclusion criteria: 1. Skin defect and infection at the puncture site of the neck; 2. Postoperative review of EC-IC bypass.

Design outcomes

Primary

Measure	Time frame
EC-IC bypass width;	—

Countries

China

Contacts

Public ContactFeng Xia

The First Affiliated Hospital of Sun Yat-sen University

fengxiar@aliyun.cn+86 13751703589

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026